Overview

Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Status:
RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD). The main questions it aims to answer are: * Safety and tolerability of the novel stem cell formulation * Potential efficacy of the novel stem cell formulation Participants will receive a single subretinal injection in their study eye and followed up for safety. This is an India only study and the product is developed indigenously.
Phase:
PHASE1
Details
Lead Sponsor:
Eyestem Research Pvt. Ltd.
Treatments:
Mycophenolic Acid
Tacrolimus